Key result
In emergency patients with VT/VF, nifekalant therapy was associated with a 2.5% incidence of QT/QTc prolongation and a 3.9% incidence of torsades de pointes.
Why the study?
What is the incidence and what are the risk factors for QT prolongation and torsades de pointes during emergency treatment with nifekalant for refractory ventricular tachyarrhythmias?
Observational (n=1,402)
Yes
What is the incidence and what are the risk factors for QT prolongation and torsades de pointes during emergency treatment with nifekalant for refractory ventricular tachyarrhythmias?
Emergency treatment with nifekalant for refractory VT/VF carries a 3.9% risk of torsades de pointes, necessitating careful QTc monitoring, especially in women and patients with underlying heart disease.
Answers are grounded in this paper and cite their sources.
Nifekalant for emergency VT/VF warrants QTc monitoring; leaves open prospective validation of risk factors and safer protocols.
Background Nifekalant, a first‐line drug for the treatment of ventricular tachycardia/ventricular fibrillation (VT/VF) in Japan, has been known to prolong the QT interval; however, the incidence of excess QT/QTc prolongation and subsequent torsades de pointes (TdP) has not yet been reported. Methods The QT/QTc interval and occurrence of TdP during nifekalant therapy were evaluated in 1402 emergency patients with VT/VF. Results Thirty‐five cases (2.5%) of QT/QTc prolongation and 54 cases (3.9%) of TdP were reported. High nifekalant doses and long QTc intervals were associated with frequent TdP. The incidence of TdP was 1.4% for QTc intervals <0.43, 3.9% for those 0.44–0.49, 5.3% for those 0.50–0.55, 7.3% for those 0.56–0.61, 11.1% for those 0.62–0.67, and 12.5% for those ≥0.68. The odds ratio for TdP was elevated in women (2.48); in patients with any heart disease (4.68), New York Heart Association (NYHA) III or IV (1.81), Forrester subset 2 or worse (2.13), depressed cardiac function (1.86), or liver dysfunction (2.06); and in patients who were receiving concomitant drugs (2.67). In 42 patients (77.8%), TdP required treatment with direct current shock or a second drug. Conclusion Nifekalant was effective for refractory VT/VF, although careful observation of the QT/QTc interval and possible occurrence of TdP is required, especially in high‐risk patients.
No takes yet. Share an insight, caveat, or question.
Katoh et al. (2013) conducted an observational in Ventricular tachycardia/ventricular fibrillation (VT/VF) (n=1,402). Nifekalant was evaluated on QT/QTc prolongation and torsades de pointes (TdP). In emergency patients with VT/VF, nifekalant therapy was associated with a 2.5% incidence of QT/QTc prolongation and a 3.9% incidence of torsades de pointes.
Synapse has enriched 10 related papers. Consider them for comparative context: